--- title: J&J's Coronavirus Vaccine Becomes Fourth to Reach Phase 3 description: J&J becomes the fourth vaccine manufacturer to enter advanced testing canonical: https://time.com/5892317/jj-coronavirus-vaccine-phase-3/ author: Alice Park article:opinion: false article:content_tier: free article:published_time: 2020-09-23T14:42:24.000Z article:modified_time: 2026-02-24T09:14:36.752Z article:section: Health og:title: Fourth COVID-19 Vaccine Starts Late Stage Testing og:description: J&J becomes the fourth vaccine manufacturer to enter advanced testing og:url: https://time.com/5892317/jj-coronavirus-vaccine-phase-3/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt6f8e945fd4e77295/698a128116d884fa12c38a1e/CGNO_270-1.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 og:image:width: 6016 og:image:height: 3384 og:image:alt: CGNO_270 (1) og:type: article twitter:card: summary_large_image twitter:title: Fourth COVID-19 Vaccine Starts Late Stage Testing twitter:description: J&J becomes the fourth vaccine manufacturer to enter advanced testing twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt6f8e945fd4e77295/698a128116d884fa12c38a1e/CGNO_270-1.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 ---  # J&J's COVID-19 Vaccine Will Enter Phase 3 Testing, the Fourth To Reach That Stage > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: September 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=b6e2b82a-8e5f-4689-a504-b211d9ab6a46&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | | Health Matters | The latest health news and expert advice on living well | Weekdays | | Worth Your Time | A weekly guide to what to watch, read, and more | Weekly | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Twice a week | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | Source: TIME, August 2026. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=b6e2b82a-8e5f-4689-a504-b211d9ab6a46&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=b6e2b82a-8e5f-4689-a504-b211d9ab6a46&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (health, weekdays), Worth Your Time (culture, weekly), D.C. Brief (Washington politics, twice weekly), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement. ### Sources * TIME Newsletters: [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=b6e2b82a-8e5f-4689-a504-b211d9ab6a46&cr=time-nl-network-2026q3-v1)  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Sep 23, 2020 2:42 PM UTC  Johnson & Johnson  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Sep 23, 2020 2:42 PM UTC Johnson & Johnson announced today (Sept. 23) that it is [launching a large-scale Phase 3 test](https://www.jnj.com/johnson-johnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssens-covid-19-vaccine-candidate) of its COVID-19 vaccine candidate, which was developed based on science supported by the National Institutes of Health. The vaccine, being tested through the company’s Janssen Pharmaceuticals arm, will be the fourth to enter late stage studies, following candidates from [Moderna](https://time.com/5872243/moderna-covid-19-vaccine-phase-three-trial/), [Pfizer-BioNTech](https://time.com/5887199/coronavirus-vaccine-race/) and [AstraZeneca](https://time.com/5887199/coronavirus-vaccine-race/). Unlike those vaccine candidates, which all require two shots, J&J’s vaccine involves a single injection. That means it could require half the number of doses to immunize the same number of people. J&J’s study, named ENSEMBLE, will recruit 60,000 volunteers across eight countries—Argentina, Brazil, Chile, Columbia, Mexico, Peru, South Africa and the U.S. Given the data showing that some groups are more vulnerable to the effects of COVID-19, Dr. Paul Stoffels, chief scientific officer at J&J, said the company and its study leaders are focusing on ensuring that the study includes a diverse population of participants. The vaccine uses a weakened cold virus, called AD26, to deliver the COVID-19 virus’s genetic material to the right immune cells in the body. Those cells then process the viral material to train the immune system to recognize and destroy any similar incoming virus. Based on studies in [hamsters](https://www.nature.com/articles/s41591-020-1070-6) and [monkeys](https://www.nature.com/articles/s41586-020-2607-z), the vaccine produced sufficient immune responses that could neutralize the virus in the lab, and early tests in people which began in mid-July produced similarly encouraging results, which Stoffels says the company will publish in coming weeks. J&J’s coronavirus vaccine relies on a platform that the company had previously used to create Zika, HIV, RSV and Ebola vaccine candidates; only the Ebola vaccine has been approved so far, and only in the European Union. However, Stoffels said in a briefing, “We have studied this vaccine platform in more than 100,000 people \[in other diseases\] so that enabled us to go very fast and optimize for a COVID-19 vaccine,” As with the other late-stage trials, this study will be supervised by the same data safety monitoring board, which will analyze the data regularly for safety signals and signs of effectiveness or futility. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which is supporting the trial, said that the timing for results from the J&J study (and the other three late-stage vaccine studies) will depend on how many cases of COVID-19 are recorded among both the vaccinated and the placebo groups. Only that comparison will give researchers a strong enough signal about whether or not a vaccine creates sufficient immunity. “I have said in the past that we predict we could have an answer from \[the first vaccine trial from Moderna\] that started in July, sometime in November or December,” he said in a briefing discussing the J&J trial. “It’s conceivable it could be earlier, that it could be October, but I think that is unlikely but not impossible. We are now in September and this trial is starting later, so I think the projection would be maybe a month or two later \[than the others\].” One factor that could save J&J some time is the fact that it’s vaccine only requires a single dose, which could cut a month off its study time—the other vaccine candidates require three to four weeks between shots. Either way, Dr. Francis Collins, director of the National Institutes of Health, said in the briefing, “People may have heard the term warp speed, and are maybe slightly nervous that it means things are going to be rushed through and that corners will be cut on safety and efficacy. I want to reassure \[everyone\] that will absolutely not happen. I doubt that many vaccine trials of this size have ever been subjected to the rigor with which these trials are evaluated.” ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/5892317/jj-coronavirus-vaccine-phase-3/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/5892317/jj-coronavirus-vaccine-phase-3/"},"headline":"J&J's COVID-19 Vaccine Will Enter Phase 3 Testing, the Fourth To Reach That Stage","datePublished":"2020-09-23T14:42:24.000Z","dateModified":"2026-02-24T09:14:36.752Z","description":"J&J becomes the fourth vaccine manufacturer to enter advanced testing","url":"https://time.com/5892317/jj-coronavirus-vaccine-phase-3/","keywords":["COVID-19"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt6f8e945fd4e77295/698a128116d884fa12c38a1e/CGNO_270-1.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Alice Park","jobTitle":"Senior Correspondent","url":"https://time.com/author/alice-park/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt6f8e945fd4e77295/698a128116d884fa12c38a1e/CGNO_270-1.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"CGNO_270 (1)","caption":"","creditText":"Johnson & Johnson","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/covid-19/","name":"COVID-19"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/5892317/jj-coronavirus-vaccine-phase-3/","name":"J&J's COVID-19 Vaccine Will Enter Phase 3 Testing, the Fourth To Reach That Stage"}}]}] ```